Market Overview:
The global antibody drug conjugates market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.
Antibody Drug Conjugates Market Trends:
Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on component, target, application and end user.
Breakup by Component:
- Monoclonal Antibodies
- Linker
- Cytotoxic Agent
- Others
Breakup by Target:
- Antibody-Protein Toxin Conjugates
- Antibody-Chelated Radionuclide Conjugates
- Antibody-Small-Molecule Drug Conjugates
- Antibody-Enzyme Conjugates
Breakup by Application:
- Lymphoma
- Ovarian Cancer
- Lung Cancer
- Breast Cancer
- Brain Tumor
- Others
Breakup by End User:
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biotechnology Companies
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2020 |
| Historical Period |
2015-2020 |
| Forecast Period |
2021-2026 |
| Units |
US$ Billion |
| Segment Coverage |
Component, Target, Application, End User, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global antibody drug conjugates market?
- What are the key regional markets?
- What is the breakup of the market based on the component?
- What is the breakup of the market based on the target?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global antibody drug conjugates market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Antibody Drug Conjugates Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Component
6.1 Monoclonal Antibodies
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Linker
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cytotoxic Agent
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Target
7.1 Antibody-Protein Toxin Conjugates
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Antibody-Chelated Radionuclide Conjugates
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Antibody-Small-Molecule Drug Conjugates
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Antibody-Enzyme Conjugates
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Application
8.1 Lymphoma
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ovarian Cancer
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Lung Cancer
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Breast Cancer
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Brain Tumor
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Specialized Cancer Centers
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Academic Research Institutes
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Biotechnology Companies
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 ADC Therapeutics SA
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.2 Astellas Pharma Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 AstraZeneca plc
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Celldex Therapeutics Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 F. Hoffmann-La Roche AG
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Gilead Sciences Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 GlaxoSmithKline Plc
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 ImmunoGen Inc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanofi S.A.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Seagen Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Sorrento Therapeutics Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.13 Takeda Pharmaceutical Company Ltd.
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
List of Figures
Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2020
Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2020
Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2020
Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2020
Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2020
Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million US$), 2015 & 2020
Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million US$), 2015 & 2020
Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million US$), 2015 & 2020
Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million US$), 2015 & 2020
Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million US$), 2015 & 2020
Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2015 & 2020
Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2020
Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million US$), 2021-2026
Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million US$), 2021-2026
Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million US$), 2021-2026
Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million US$), 2021-2026
Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
Table 8: Global: Antibody Drug Conjugates Market: Key Players